Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study

Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study

BackgroundFor a majority of patients with metastatic colorectal cancer (mCRC) with MS stable (MSS) or mismatch repair proficient (pMMR), the role of immunotherapy is undetermined. This study investigated the efficacy and safety of camrelizumab when added to XELOX chemotherapy plus bevacizumab or reg...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Hong Zhou, Yuehui Wang, Yanfang Lin, Wenjie Cai, Xiaofeng Li, Xiaomeng He
Format: article
Langue:EN
Publié: Frontiers Media S.A. 2021
Sujets:
colorectal cancer
camrelizumab
immune checkpoint inhibitor
microsatellite stable
bevacizumab
regorafenib
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Accès en ligne:https://doaj.org/article/1778ffc6421b4cb1aa24fb47cd56073e
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/1778ffc6421b4cb1aa24fb47cd56073e

Documents similaires